The tweet was deleted by the author.
But we saved everything 🙂.
NeuroPace Inc is set to present new findings from the NAUTILUS Study, the first and only randomized trial of neuromodulation for drug-resistant idiopathic generalized epilepsy (IGE), at the 2026 AAN Annual Meeting.
The presentation, led by Dr. Martha Morrell, will provide the latest insights into this key research advancement. Those unable to attend in person are encouraged to watch the event online to stay informed on the evolving landscape of neuromodulation therapy for challenging epilepsy cases.
NeuroPace previously released NAUTILUS Study results, highlighting advances in neuromodulation for drug-resistant IGE at the 2026 AAN meeting. The company has also encouraged epilepsy patients with uncontrolled seizures to assess their suitability for the RNS System through an online quiz. Both initiatives reflect ongoing efforts to expand treatment options for challenging epilepsy cases.